RHN van Schaik

1.3k total citations · 1 hit paper
9 papers, 856 citations indexed

About

RHN van Schaik is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, RHN van Schaik has authored 9 papers receiving a total of 856 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 3 papers in Pediatrics, Perinatology and Child Health and 3 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in RHN van Schaik's work include Pharmacogenetics and Drug Metabolism (6 papers), Renal Transplantation Outcomes and Treatments (2 papers) and Pharmacological Effects and Toxicity Studies (2 papers). RHN van Schaik is often cited by papers focused on Pharmacogenetics and Drug Metabolism (6 papers), Renal Transplantation Outcomes and Treatments (2 papers) and Pharmacological Effects and Toxicity Studies (2 papers). RHN van Schaik collaborates with scholars based in Netherlands, United States and New Zealand. RHN van Schaik's co-authors include Wolfgang Sadée, Teri E. Klein, Alexander A. Vinks, Daqing Wang, Yijing He, Brian S. Decker, Kelly A. Birdwell, JJ Swen, Catherine M. Stein and JS Leeder and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Pharmacology Biochemistry and Behavior and University of Groningen research database (University of Groningen / Centre for Information Technology).

In The Last Decade

RHN van Schaik

9 papers receiving 842 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

2015 499 citations Kelly A. Birdwell, Brian S. Decker et al. Clinical Pharmacology & Therapeutics profile →

Peers

RHN van Schaik

PHARM

TRANS

PPCH

SURGE

ONCOL

Ilse P. van der Heiden Netherlands

Sara Bremer Norway

Kathleen M. Tornatore United States

JJ Swen Netherlands

Nassim Djebli France

Azemi Barama Canada

HU Yong-fang China

Aurélie Prémaud France

Morton B. Brown United States

Robert R. Mayo United States

Ilse P. van der Heiden Netherlands

RHN van Schaik

314 ×0.8

PHARM

338 ×1.0

TRANS

409 ×1.3

PPCH

113 ×0.8

SURGE

285 ×2.2

ONCOL

Citations per year, relative to RHN van Schaik RHN van Schaik (= 1×) peers Ilse P. van der Heiden

Countries citing papers authored by RHN van Schaik

Since Specialization

Citations

This map shows the geographic impact of RHN van Schaik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by RHN van Schaik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites RHN van Schaik more than expected).

Fields of papers citing papers by RHN van Schaik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by RHN van Schaik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by RHN van Schaik. The network helps show where RHN van Schaik may publish in the future.

Co-authorship network of co-authors of RHN van Schaik

This figure shows the co-authorship network connecting the top 25 collaborators of RHN van Schaik. A scholar is included among the top collaborators of RHN van Schaik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with RHN van Schaik. RHN van Schaik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Birdwell, Kelly A., Brian S. Decker, Julia M. Barbarino, et al.. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Data Archiving and Networked Services (DANS). 63 indexed citations

2.

Birdwell, Kelly A., Brian S. Decker, Catherine M. Stein, et al.. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clinical Pharmacology & Therapeutics. 98(1). 19–24. 499 indexed citations breakdown →

3.

Janssen, Paddy K.C., RHN van Schaik, Aeilko H. Zwinderman, Berend Olivier, & Marcel D. Waldinger. (2014). The 5-HT1A receptor C(1019)G polymorphism influences the intravaginal ejaculation latency time in Dutch Caucasian men with lifelong premature ejaculation. Pharmacology Biochemistry and Behavior. 121. 184–188. 34 indexed citations

4.

Swen, Jesse J., Marga Nijenhuis, Anthonius de Boer, et al.. (2011). Pharmacogenetics: From bench to byte. University of Groningen research database (University of Groningen / Centre for Information Technology). 5(6). 16 indexed citations

5.

Teichert, Martina, et al.. (2009). Genotypes Associated With Reduced Activity of VKORC1 and CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial Treatment Period. Clinical Pharmacology & Therapeutics. 85(4). 379–386. 28 indexed citations

6.

Schaik, RHN van, J. C. M. Witteman, Albert Hofman, et al.. (2008). Genetic Variation in the CYP2D6 Gene Is Associated With a Lower Heart Rate and Blood Pressure in β-Blocker Users. Clinical Pharmacology & Therapeutics. 85(1). 45–50. 113 indexed citations

7.

Becker, Matthijs L., et al.. (2007). Cytochrome P450 2C9 *2 and *3 Polymorphisms and the Dose and Effect of Sulfonylurea in Type II Diabetes Mellitus. Clinical Pharmacology & Therapeutics. 83(2). 288–292. 83 indexed citations

8.

Schaik, RHN van, Ilse P. van der Heiden, Alberta A. H. J. Thiadens, et al.. (2003). CYP3A4, CYP3A5 and MDR‐1 Variant Alleles in The Dutch Caucasian Population. Clinical Pharmacology & Therapeutics. 73(2). 15 indexed citations

9.

Schaik, RHN van, et al.. (2003). Tacrolimus, but not cyclosporine drug levels, are correlated with CYP3A5*3 and CYP3A4*1B genotype; no correlation with the MDR‐1 C3435T polymorphism. Clinical Pharmacology & Therapeutics. 73(2). 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact